Clinical Trial

This is an Open-label, Non-randomized Study to Assess the Pharmacokinetics (PK) of VCT220 in Healthy Volunteers When Administered With Rifampin or Itraconazole

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-center, open-label, single-arm, fixed-sequence Phase I study in healthy participants to evaluate the effect of multiple doses of rifampin or itraconazole on the pharmacokinetics (PK) of VCT220 and its metabolite VCT289. Cohort 1 will assess the impact of rifampin (600 mg once daily) on VCT220 (160 mg single dose). Cohort 2 will assess the impact of itraconazole (200 mg once daily) on VCT220 (40 mg single dose). A total of 32 healthy subjects will be enrolled, 16 in each cohort.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-29; most recent amendment 2026-03-25.
Status change: Active, Not Recruiting → Completed 2026-03-25
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-08-12
Trial Details
NCT Number NCT07056842
Lead Sponsor Vincentage Pharma Co., Ltd
Conditions Obesity & Overweight
Enrollment 32 participants
Start Date 2025-07-20
Primary Completion 2025-08-11 (estimated)
Study Completion 2025-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-31